Simplifying Global Compliance
Appeals Court Upholds Exec Exclusion; Rejects ‘Arbitrary’ Penalty Period
Washington Drug Letter
A U.S. appeals court has ruled HHS was “unambiguously” justified in excluding three former Purdue Pharma executives from federal healthcare programs after they pleaded guilty to charges the company illegally marketed and promoted its painkiller Oxycontin.
To View This Article:
Buy This Article Now
Copyright ©2018. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing